Company intelligence / Profile preview

Bioxis Pharmaceuticals

Lyon, Auvergne-Rhône-Alpes, France

Ownership: Private
Employees: ~23
Development stage: Preclinical

Overview

Bioxis Pharmaceuticals is developing innovative regenerative medical products, including the pre-clinical monophasic tissular inductor MTI12 based on proprietary chitosan technology. Its hyaluronic acid-based dermal filler line, CYTOSIAL, has been launched commercially with exclusive distribution agreements in Europe and Asia. The company focuses on improving outcomes in dermatology and aesthetic medicine through advanced biomaterials

Therapeutic areas: OtherDermatology
Modalities: Biomaterial scaffoldChitosan-based medical deviceHyaluronic acid-based dermal filler
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

MTI-12

Pre-clinical

Partnerships

Exclusive distribution agreements for CYTOSIAL in Europe and Asia

Beyond the preview

Go deeper on Bioxis Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bioxis Pharmaceuticals.

Explore the full profile